Equities researchers at Cantor Fitzgerald issued their FY2016 earnings estimates for Agile Therapeutics in a report released on Tuesday. Cantor Fitzgerald analyst E. Piros now expects that the firm will earn ($0.59) per share for the year, up from their previous forecast of ($0.78). Cantor Fitzgerald has a "Buy" rating and a $37.00 price target on the stock. Cantor Fitzgerald also issued estimates for Agile Therapeutics' FY2017 earnings at ($1.42) EPS. Raymond James Financial, Inc. initiated coverage on Flexion Therapeutics in a research report on Thursday, December 22nd. Finally, BCS dropped their target price on Flexion Therapeutics from $0.65 to $0.02 in a research report on Tuesday, November 8th. One analyst has rated the stock with a hold rating and six have issued a buy rating to the stock. If you are viewing this story on another publication, it was illegally copied and reposted in violation of USA and worldwide copyright legislation. The original version of this article can be viewed at https://www.com-unik.info/2017/01/13/cantor-fitzgerald-weighs-in-on-agile-therapeutics-inc-s-fy2016-earnings-agrx.html.
Axsome Therapeutics (NASDAQ:AXSM) opened at 6.45 on Tuesday. The company's 50-day moving average is $6.63 and its 200-day moving average is $7.27. The company's market capitalization is $528.24 million. Agile Therapeutics has a 52-week low of $1.82 and a 52-week high of $8.65.
Flexion Therapeutics (NASDAQ:FLXN) last announced its earnings results on Monday, November 7th. The biopharmaceutical company reported ($0.08) earnings per share for the quarter, beating the Zacks' consensus estimate of ($0.19) by $0.11.
A number of hedge funds and other institutional investors have recently modified their holdings of the company. RTW Investments LLC purchased a new position in shares of Abeona Therapeutics during the third quarter valued at about $116,000. ProShare Advisors LLC now owns 18,320 shares of the specialty pharmaceutical company's stock valued at $274,000 after buying an additional 783 shares in the last quarter. American International Group Inc. now owns 10,656 shares of the specialty pharmaceutical company's stock valued at $159,000 after buying an additional 810 shares in the last quarter. 461,786 shares of the company's stock traded hands. Rhumbline Advisers increased its position in shares of Flexion Therapeutics by 18.3% in the third quarter. Finally, Bank of New York Mellon Corp bought a new stake in Axsome Therapeutics during the second quarter valued at $161,000. Teachers Advisors Inc. now owns 19,401 shares of the specialty pharmaceutical company's stock valued at $148,000 after buying an additional 4,497 shares during the last quarter. The stock was sold at an average price of $18.46, for a total value of $184,600.00. The disclosure for this sale can be found here.
Abeona Therapeutics, Inc (Abeona), formerly PlasmaTech Biopharmaceuticals, Inc, is focused on developing and delivering gene therapy and plasma-based products for rare diseases. The Company is engaged in developing therapies for the management of central nervous system (CNS) disorders, including pain. The Company's lead product candidate, Zilretta, is a late-stage, injectable, extended-release, intra-articular (IA) investigational steroid.